ATE443714T1 - Lang wirkende peptidinhibitoren der virusfusion mit körperzellen bei viralen infektionen - Google Patents

Lang wirkende peptidinhibitoren der virusfusion mit körperzellen bei viralen infektionen

Info

Publication number
ATE443714T1
ATE443714T1 AT02014617T AT02014617T ATE443714T1 AT E443714 T1 ATE443714 T1 AT E443714T1 AT 02014617 T AT02014617 T AT 02014617T AT 02014617 T AT02014617 T AT 02014617T AT E443714 T1 ATE443714 T1 AT E443714T1
Authority
AT
Austria
Prior art keywords
long
viral infections
peptide inhibitors
body cells
virus fusion
Prior art date
Application number
AT02014617T
Other languages
English (en)
Inventor
Dominique Bridon
Robert Dufresne
Nissab Boudjellab
Martin Robitaille
Peter Milner
Original Assignee
Conjuchem Biotechnologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26832297&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE443714(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Conjuchem Biotechnologies Inc filed Critical Conjuchem Biotechnologies Inc
Application granted granted Critical
Publication of ATE443714T1 publication Critical patent/ATE443714T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
AT02014617T 1999-05-17 2000-05-17 Lang wirkende peptidinhibitoren der virusfusion mit körperzellen bei viralen infektionen ATE443714T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13440699P 1999-05-17 1999-05-17
US15340699P 1999-09-10 1999-09-10

Publications (1)

Publication Number Publication Date
ATE443714T1 true ATE443714T1 (de) 2009-10-15

Family

ID=26832297

Family Applications (2)

Application Number Title Priority Date Filing Date
AT00932570T ATE226593T1 (de) 1999-05-17 2000-05-17 Lang wirkende peptidinhibitoren der virusfusion mit körperzellen bei viralen infektionen
AT02014617T ATE443714T1 (de) 1999-05-17 2000-05-17 Lang wirkende peptidinhibitoren der virusfusion mit körperzellen bei viralen infektionen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT00932570T ATE226593T1 (de) 1999-05-17 2000-05-17 Lang wirkende peptidinhibitoren der virusfusion mit körperzellen bei viralen infektionen

Country Status (14)

Country Link
US (4) US7582301B1 (de)
EP (3) EP1179012B2 (de)
JP (3) JP4216480B2 (de)
CN (1) CN1351611A (de)
AT (2) ATE226593T1 (de)
AU (1) AU761591B2 (de)
BR (1) BR0010757A (de)
CA (1) CA2372338A1 (de)
DE (2) DE60000665T3 (de)
DK (1) DK1264840T3 (de)
ES (2) ES2334106T3 (de)
HK (1) HK1053128A1 (de)
PT (1) PT1264840E (de)
WO (1) WO2000069902A1 (de)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4216480B2 (ja) 1999-05-17 2009-01-28 コンジュケム バイオテクノロジーズ インコーポレイテッド ウイルス感染の長期持続性融合ペプチドインヒビター
US6514500B1 (en) * 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
US20040266673A1 (en) * 2002-07-31 2004-12-30 Peter Bakis Long lasting natriuretic peptide derivatives
US7601691B2 (en) 1999-05-17 2009-10-13 Conjuchem Biotechnologies Inc. Anti-obesity agents
US6887470B1 (en) 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
ES2209885T3 (es) 1999-05-17 2004-07-01 Conjuchem, Inc. Peptidos insulinotropicos de larga duracion.
US20090175821A1 (en) * 1999-05-17 2009-07-09 Bridon Dominique P Modified therapeutic peptides with extended half-lives in vivo
JP4280070B2 (ja) 2001-02-16 2009-06-17 コンジュケム バイオテクノロジーズ インコーポレイテッド 胃腸疾患および胃腸障害の処置のための長期持続性グルカゴン様ペプチド２（ｇｌｐ−２）
ES2242860T3 (es) 2001-05-31 2005-11-16 Conjuchem, Inc. Inhibidores peptidicos de fusion de larga vida contra infecciones por vih.
WO2002103026A2 (en) 2001-06-15 2002-12-27 F. Hoffmann-La Roche Ag Method for the recombinant production of peptidic antiviral fusion inhibitors, and acetylation of gb41 fragments
WO2004029201A2 (en) * 2002-09-24 2004-04-08 Frontier Biotechnologies Co., Ltd Peptide derivative fusion inhibitors of hiv infection
US7556813B2 (en) * 2002-09-27 2009-07-07 Trimeris, Inc. Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides
CA2443365C (en) * 2002-11-19 2010-01-12 F. Hoffmann-La Roche Ag Methods for the recombinant production of antifusogenic peptides
US20090123468A1 (en) 2003-10-24 2009-05-14 Gencia Corporation Transducible polypeptides for modifying metabolism
US8062891B2 (en) 2003-10-24 2011-11-22 Gencia Corporation Nonviral vectors for delivering polynucleotides to plants
WO2005056752A2 (en) 2003-10-24 2005-06-23 Gencia Corporation Methods and compositions for delivering polynucleotides
US8507277B2 (en) 2003-10-24 2013-08-13 Gencia Corporation Nonviral vectors for delivering polynucleotides
US8133733B2 (en) 2003-10-24 2012-03-13 Gencia Corporation Nonviral vectors for delivering polynucleotides to target tissues
BRPI0510117A (pt) * 2004-04-23 2007-09-25 Conjuchem Biotechnologies Inc método para purificação de conjugados de albumina
US7723063B2 (en) * 2004-04-28 2010-05-25 Intrinsic Lifesciences Methods for measuring levels of bioactive human hepcidin
JP2008505059A (ja) * 2004-05-06 2008-02-21 コンジュシェム バイオテクノロジーズ インコーポレイティド 特異的ウイルス標的用化合物
US8039432B2 (en) * 2005-11-09 2011-10-18 Conjuchem, Llc Method of treatment of diabetes and/or obesity with reduced nausea side effect
US20070269863A1 (en) * 2005-12-22 2007-11-22 Bridon Dominique P Process for the production of preformed conjugates of albumin and a therapeutic agent
CN100475270C (zh) 2006-01-20 2009-04-08 清华大学 一种***的药物及其应用
CN101002945B (zh) 2006-01-20 2012-09-05 清华大学 一种用于肿瘤治疗的新型复合物
ATE537183T1 (de) 2006-02-02 2011-12-15 Trimeris Inc Hiv-fusionshemmerpeptide mit verbesserten biologischen eigenschaften
CN100366633C (zh) * 2006-04-18 2008-02-06 河北师范大学 棕点湍蛙抗病毒多肽及其在制药中的应用
TW200817438A (en) 2006-08-17 2008-04-16 Hoffmann La Roche A conjugate of an antibody against CCR5 and an antifusogenic peptide
MX2009001204A (es) 2006-08-17 2009-02-11 Hoffmann La Roche Conjugado de un anticuerpo cointra ccr5 y un peptido antifusogenico.
US20090099074A1 (en) * 2007-01-10 2009-04-16 Conjuchem Biotechnologies Inc. Modulating food intake
US20090088378A1 (en) * 2007-01-12 2009-04-02 Omar Quraishi Long lasting inhibitors of viral infection
TW200902544A (en) 2007-03-13 2009-01-16 Hoffmann La Roche Peptide-complement conjugates
CA2687700A1 (en) * 2007-05-16 2008-11-27 Conjuchem Biotechnologies Inc. Cysteic acid derivatives of anti-viral peptides
CL2008002092A1 (es) 2007-07-20 2009-05-29 Hoffmann La Roche Conjugado que contiene dos o mas peptidos antifusogenicos y un anticuerpo anti-cd-4; metodo de produccion; composicion farmaceutica que lo comprende; polipeptidos antifusogenicos y uso del conjugado para tratar infecciones viricas.
EP2594583A1 (de) 2007-08-08 2013-05-22 Novozymes Biopharma DK A/S Transferrinvarianten und Konjugate
EP2036980A1 (de) * 2007-09-14 2009-03-18 Gruber, Jens Herabregulation der Genexpression mittels Nukleinsäure-beladener virusähnlicher Partikel
CN102026666B (zh) * 2007-12-11 2013-10-16 常山凯捷健生物药物研发（河北）有限公司 促胰岛素肽缀合物制剂
CN106986933A (zh) 2009-02-11 2017-07-28 阿尔布梅迪克斯医疗公司 白蛋白变体和缀合物
JP5646620B2 (ja) * 2009-07-17 2014-12-24 インダストリー アカデミック コーポレーション ファウンデーション， ハルリム ユニバーシティー リポソームに被包されたオリゴヌクレオチド及びエピトープを含む免疫増強用組成物
US8748380B2 (en) 2009-10-30 2014-06-10 Novozymes Biopharma Dk A/S Albumin variants
WO2011124718A1 (en) 2010-04-09 2011-10-13 Novozymes A/S Albumin derivatives and variants
CN103108884A (zh) 2010-09-14 2013-05-15 弗·哈夫曼-拉罗切有限公司 Serpin-finger融合多肽
US20130225496A1 (en) 2010-11-01 2013-08-29 Novozymes Biopharma Dk A/S Albumin Variants
CN104011072B (zh) 2011-05-05 2018-10-12 阿尔布梅迪克斯医疗有限公司 白蛋白变体
EP3384938A1 (de) 2011-09-12 2018-10-10 Moderna Therapeutics, Inc. Manipulierte nukleinsäuren und verfahren zur verwendung davon
EP2780364A2 (de) 2011-11-18 2014-09-24 Eleven Biotherapeutics, Inc. Proteine mit verbesserter halbwertzeit und anderen eigenschaften
KR20140136934A (ko) 2012-03-16 2014-12-01 노보자임스 바이오파마 디케이 에이/에스 알부민 변이체
CA2868391A1 (en) 2012-04-02 2013-10-10 Stephane Bancel Polynucleotides comprising n1-methyl-pseudouridine and methods for preparing the same
AU2013243947A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
EP2834264A1 (de) 2012-04-04 2015-02-11 Yeda Research and Development Co. Ltd. Lipopeptidkonjugate mit sphingolipid und aus hiv gp41 gewonnenen peptiden
EP2917233A1 (de) 2012-11-08 2015-09-16 Novozymes Biopharma DK A/S Albuminvarianten
KR20150118123A (ko) 2013-02-16 2015-10-21 노보자임스 바이오파마 디케이 에이/에스 약동학적 동물 모델
WO2014165452A1 (en) * 2013-04-03 2014-10-09 The Regents Of The University Of California Compositions and methods for inhibiting viral activity
EP3063171B1 (de) 2013-11-01 2019-07-24 University Of Oslo Albuminvarianten und verwendungen davon
CN103864921B (zh) * 2014-01-16 2017-12-26 苏州大学 双重靶向治疗癌症的叶酸‑阿霉素免疫制剂及其制备方法
US20170107294A1 (en) 2014-03-21 2017-04-20 Nordlandssykehuset Hf Anti-cd14 antibodies and uses thereof
WO2015164615A1 (en) 2014-04-24 2015-10-29 University Of Oslo Anti-gluten antibodies and uses thereof
EP3337816B1 (de) 2015-08-20 2024-02-14 Albumedix Ltd Albumin-varianten und -konjugate
US11168131B2 (en) 2015-11-10 2021-11-09 Visterra, Inc. Antibody molecule-drug conjugates and uses thereof
CN110337590A (zh) 2016-11-04 2019-10-15 奥胡斯大学 以新生儿Fc受体过表达为特征的肿瘤的识别和治疗
WO2018096396A1 (en) 2016-11-22 2018-05-31 University Of Oslo Albumin variants and uses thereof
CA3049449A1 (en) 2017-01-18 2018-07-26 Visterra, Inc. Antibody molecule-drug conjugates and uses thereof
CN111303245B (zh) * 2020-02-21 2023-06-27 成都奥达生物科技有限公司 一种抗合胞病毒膜融合抑制剂
CN116710146A (zh) 2020-04-03 2023-09-05 威特拉公司 抗体分子-药物偶联物及其用途
WO2021211303A1 (en) * 2020-04-14 2021-10-21 Contrafect Corporation Antiviral, bacteriophage-derived polypeptides and their use against viruses

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3719667A (en) 1970-08-24 1973-03-06 Lilly Co Eli Epimerization of 6-acylamido and 6-imido penicillin sulfoxide esters
US3840556A (en) 1971-05-28 1974-10-08 Lilly Co Eli Penicillin conversion by halogen electrophiles and anti-bacterials derived thereby
US4652629A (en) * 1985-07-03 1987-03-24 The Salk Institute For Biological Studies Synthetic peptide-based anti-rabies compositions and methods
US5116944A (en) * 1989-12-29 1992-05-26 Neorx Corporation Conjugates having improved characteristics for in vivo administration
US5612034A (en) * 1990-10-03 1997-03-18 Redcell, Inc. Super-globuling for in vivo extended lifetimes
DK0578728T3 (da) 1991-04-05 1999-04-12 Genentech Inc Inhibitorer for aggregering af blodplader, hvilke inhibitorer har høj specificitet for GP IIbIIIa
FR2686899B1 (fr) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
WO1994002505A1 (en) 1992-07-20 1994-02-03 Duke University Compounds which inhibit hiv replication
GB9316895D0 (en) * 1993-08-13 1993-09-29 Guy S And St Thomas Hospitals Hepatoselective insulin analogues
EP0602290B1 (de) * 1992-12-04 1999-08-25 ConjuChem, Inc. Antikörper-konjugiertes-Hepatitis B-Oberflächenantigen und dessen Verwendung
US5614487A (en) 1993-05-28 1997-03-25 Genentech, Inc. Sustained release pharmaceutical composition
US6017536A (en) 1993-06-07 2000-01-25 Trimeris, Inc. Simian immunodeficiency virus peptides with antifusogenic and antiviral activities
US6479055B1 (en) 1993-06-07 2002-11-12 Trimeris, Inc. Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission
US5464933A (en) * 1993-06-07 1995-11-07 Duke University Synthetic peptide inhibitors of HIV transmission
US6518013B1 (en) * 1993-06-07 2003-02-11 Trimeris, Inc. Methods for the inhibition of epstein-barr virus transmission employing anti-viral peptides capable of abrogating viral fusion and transmission
US6342225B1 (en) * 1993-08-13 2002-01-29 Deutshces Wollforschungsinstitut Pharmaceutical active conjugates
US6103236A (en) 1995-05-10 2000-08-15 Kyowa Hakko Kogyo Co., Ltd. Toxin conjugates
US6576636B2 (en) * 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
JP4086936B2 (ja) 1996-10-03 2008-05-14 株式会社ブリヂストン ダミーウェハ
US6150088A (en) * 1997-04-17 2000-11-21 Whitehead Institute For Biomedical Research Core structure of gp41 from the HIV envelope glycoprotein
WO1999024076A2 (en) * 1997-11-07 1999-05-20 Conjuchem, Inc. Salicylate derivatized therapeutic and diagnostic agents
ES2178854T3 (es) * 1997-11-07 2003-01-01 Conjuchem Inc Bibliotecas de marcadores de afinidad para albumina de suero humano.
US6107489A (en) * 1998-03-17 2000-08-22 Conjuchem, Inc. Extended lifetimes in vivo renin inhibitors
IL133053A0 (en) * 1998-03-23 2001-03-19 Conjuchem Inc Local delivery of long lasting therapeutic agents
US6258782B1 (en) * 1998-05-20 2001-07-10 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
US20030190740A1 (en) * 1998-10-13 2003-10-09 The University Of Georgia Research Foundation, Inc Stabilized bioactive peptides and methods of identification, synthesis, and use
BR9914519A (pt) * 1998-10-13 2001-07-03 Univ Georgia Res Found Peptìdios bioativos estabilizados e métodos de identificação, sìntese e uso
JP4216480B2 (ja) 1999-05-17 2009-01-28 コンジュケム バイオテクノロジーズ インコーポレイテッド ウイルス感染の長期持続性融合ペプチドインヒビター
US20090175821A1 (en) * 1999-05-17 2009-07-09 Bridon Dominique P Modified therapeutic peptides with extended half-lives in vivo
DE19926154A1 (de) 1999-06-09 2000-12-14 Ktb Tumorforschungs Gmbh Verfahren zur Herstellung einer injizierbaren Arzneimittelzubereitung
DE19926475A1 (de) 1999-06-10 2000-12-14 Ktb Tumorforschungs Gmbh Träger-Pharmaka-Konjugate
US7090851B1 (en) 1999-09-10 2006-08-15 Conjuchem Inc. Long lasting fusion peptide inhibitors of viral infection
ES2242860T3 (es) 2001-05-31 2005-11-16 Conjuchem, Inc. Inhibidores peptidicos de fusion de larga vida contra infecciones por vih.
BRPI0510117A (pt) * 2004-04-23 2007-09-25 Conjuchem Biotechnologies Inc método para purificação de conjugados de albumina
JP2008505059A (ja) 2004-05-06 2008-02-21 コンジュシェム バイオテクノロジーズ インコーポレイティド 特異的ウイルス標的用化合物

Also Published As

Publication number Publication date
WO2000069902A1 (en) 2000-11-23
JP2008101021A (ja) 2008-05-01
PT1264840E (pt) 2010-01-04
DE60000665T3 (de) 2009-10-29
DK1264840T3 (da) 2009-11-16
EP1264840B1 (de) 2009-09-23
US20080199483A1 (en) 2008-08-21
US7608271B2 (en) 2009-10-27
AU761591B2 (en) 2003-06-05
HK1053128A1 (en) 2003-10-10
JP2009167208A (ja) 2009-07-30
EP1179012B1 (de) 2002-10-23
EP1179012B9 (de) 2003-09-10
US20080176794A1 (en) 2008-07-24
ES2185595T3 (es) 2003-05-01
DE60000665T2 (de) 2003-06-26
BR0010757A (pt) 2002-02-19
EP2110381A1 (de) 2009-10-21
AU5027100A (en) 2000-12-05
US20050070475A1 (en) 2005-03-31
ES2334106T3 (es) 2010-03-05
EP1179012A1 (de) 2002-02-13
EP1264840A1 (de) 2002-12-11
JP2002544287A (ja) 2002-12-24
DE60000665D1 (de) 2002-11-28
JP4216480B2 (ja) 2009-01-28
DE60043021D1 (de) 2009-11-05
CN1351611A (zh) 2002-05-29
ATE226593T1 (de) 2002-11-15
EP1179012B2 (de) 2009-07-15
ES2185595T5 (es) 2009-12-17
CA2372338A1 (en) 2000-11-23
US7582301B1 (en) 2009-09-01

Similar Documents

Publication Publication Date Title
ATE443714T1 (de) Lang wirkende peptidinhibitoren der virusfusion mit körperzellen bei viralen infektionen
DK1180121T3 (da) Langtidsvirkende insulinotrope peptider
EA200701386A1 (ru) Полиалкиленгликоль с остатком для конъюгации биологически активного соединения
NO995263L (no) Konjugater av polyetylenglykol og interferon-<alfa> for terapi av infeksjoner
BR9812547A (pt) Proteìnas de fusão compreendendo proteìnas hiv-1 tat e/ou nef
CU23048A3 (es) Aminoacidos ciclicos y derivados de los mismos, utiles como agentes farmaceuticos
FI933740A (fi) PEG-interferonkonjugat
LU92175I2 (fr) Lixisénatide
DE60037450D1 (de) Funf-helix protein
DK0633721T3 (da) Rensning af blodplader med 8-metoxypsoralen
NO20014857L (no) Makrocykliske peptider aktive mot Hepatitt C virus
DE69632256D1 (de) Antivirale proteine, dafür kodierende dna, und deren verwendung
ATE425188T1 (de) Physiologisch wirksames polypeptidkonjugat mit verlängerter in vivo halbwertszeit
ATE516820T1 (de) Pegyliertes interleukin 10
TR200001961T2 (tr) Ifnar 2/IFN kompleksi.
DE69011122D1 (de) Rubella-e1 und c peptide.
NO983054L (no) Virale rekombinante pseudopartikler og anvendelse som vaksiner og som anti-tumormiddel
ES2156731A1 (es) Utilizacion del acido tranexamico para la preparacion de una composicion de fibrinogeno humano.
DE60010230D1 (de) Pharmazeutische zusammensetzung von hydrophob modifizierten hedgehog-proteinen und deren verwendung
DK0739201T3 (da) Mikrogranuler af 5-nitro-imidazolderivater
TH52654A (th) แอนตี-แอนจิโอจินิก เปปไทด์ ที่มีอายุยาวนาน

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1264840

Country of ref document: EP